Aniruddha Adhikari

PeerJ Editor

Summary

Dr. Adhikari is a highly accomplished Biochemist currently associated with University of California at Los Angeles (UCLA), USA. Dr. Adhikari's research is focused on the development of nanohybrid drug delivery systems and nanomedicines for the treatment of chronic diseases. His particular focus was to explore the therapeutic potential of nanomaterials against chronic diseases where redox modulation plays a crucial role with an emphasis on their molecular mechanism of action including bio-molecular interactions, toxicity, pharmacokinetics and pharmacodynamics. Dr. Adhikari's seminal work on the chemoprevention of bilirubin encephalopathy has led to the discovery of a new and groundbreaking one-of-its-kind nanomedicine, which is currently under phase 2 clinical trial. His current research interest includes bacteriophage mediated nanotherapy and stimuli-responsive antibody conjugated nanomaterials.

Dr. Adhikari has received numerous prestigious national and international awards and grants for his research contributions. Most notable ones are Gandhian Young Technological Innovation (GYTI) Award/Appreciation from the Rashtrapati Bhavan (Office of the President, Republic of India), DMM Travel Grant from Company of Biologists, UK, Nano-challenge Award, Indo-US and four GRC Travel Grants from Gordon Research Conference, USA.

Dr. Adhikari's research contributions are widely acknowledged, and in his short research career span of about seven years he has published more than 50 research articles in high-impact prestigious international peer-reviewed journals (h-index: 13, i-10 index: 17), filed 3 patents, delivered lectures in 16 international conferences. Additionally, he has twice served as the discussion leader at Gordon Research Seminar (GRS). He also serves as the Editorial Board member and reviewer of various journals.

Biomaterials Biophysical Chemistry Nanomaterials & Nanochemistry Photochemistry Soft Matter Spectroscopy Surfaces & Interfaces Toxicology